LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Начало・Списък с акции・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

181.99 -0.62

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

179.25

Максимум

185.95

Ключови измерители
By Trading Economics
Приходи	112M 117M
Продажби	115M
P/E Средно за сектора	81.352 77.671
Марж на печалбата	101.569
Служители	68
EBITDA	87M 149M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+31.03% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-485M 3.6B
Предишно отваряне	182.61
Предишно затваряне	181.99

Настроения в новините

By Acuity

56%

44%

329 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

102.5 / 109.24 Подкрепа & съпротива

Ligand Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10.12.2025 г., 21:46 ч. UTC

Печалби

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10.12.2025 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise After Fed Rate Cut -- Market Talk

10.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10.12.2025 г., 23:20 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10.12.2025 г., 23:15 ч. UTC

Печалби

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10.12.2025 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10.12.2025 г., 22:45 ч. UTC

Пазарно говорене

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10.12.2025 г., 22:40 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:00 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10.12.2025 г., 21:53 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

10.12.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 21:33 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10.12.2025 г., 21:32 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10.12.2025 г., 21:25 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10.12.2025 г., 21:16 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10.12.2025 г., 21:15 ч. UTC

Печалби

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Сравнение с други в отрасъла

Ценова промяна

Ligand Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

31.03% нагоре

12-месечна прогноза

Среден 243.5 USD 31.03%

Висок 275 USD

Нисък 220 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ligand Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ligand Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

102.5 / 109.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

329 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.